Vera Therapeutics, Inc.
No enriched coverage for $VERA in the last 7 days.
No SEC Form 4 filings for $VERA in the last 30 days.
See all $VERA insider activity →Vera Therapeutics (Nasdaq: VERA) said its Compensation Committee granted inducement awards on July 6, 2026 to eight new employees under its 2024 Inducement Plan. Awards include non-qualified stock options for 32,100 shares and RSUs for 16,050 shares. Options exercise at $40.13, the July 6 closing price, and both options and RSUs vest over four years.
Fordyce Marshall (PRESIDENT AND CEO) sold 46,250 shares of Vera Therapeutics, Inc. (VERA) at an average of $42.30 ($40.78–$43.59, $1.96M total) across 4 trades on 2026-07-07 under a Rule 10b5-1 trading plan.
Vera Therapeutics (Nasdaq: VERA) said Chief Regulatory Officer William Turner plans to retire in the third quarter and become Strategic Advisor. Nancy Boman, M.D., Ph.D., will succeed him as Chief Regulatory Officer. The company links Turner’s tenure to the accelerated approval of TRUTAKNA (atacicept-vymj) for IgA nephropathy proteinuria.
Recent VERA coverage spans regulation, corporate actions and insider activity.
This is a routine equity-inducement grant with a defined strike price and vesting schedule, with limited direct impact on near-term fundamentals.
This is an insider sale disclosure, not a fundamental update, but it can modestly affect near-term sentiment.
Management/regulatory leadership transition at a commercial-stage biotech with an accelerated approval recently granted.
Board and officer transition in regulatory leadership can shift regulatory strategy and execution cadence, but no new regulatory outcome is disclosed.
FDA accelerated approval based on interim ORIGIN 3 proteinuria results is a near-term positive catalyst, but durability hinges on ORIGIN 3 kidney-function confirmation.
alphai scores every news story that mentions VERA with an AI model for sentiment and relevance, and aggregates insider trades from Vera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vera Therapeutics (Nasdaq: VERA) said its Compensation Committee granted inducement awards on July 6, 2026 to eight new employees under its 2024 Inducement Plan. Awards include non-qualified stock options for 32,100 shares and RSUs for 16,050 shares. Options exercise at $40.13, the July 6 closing price, and both options and RSUs vest over four years.
2 min readFordyce Marshall (PRESIDENT AND CEO) sold 46,250 shares of Vera Therapeutics, Inc. (VERA) at an average of $42.30 ($40.78–$43.59, $1.96M total) across 4 trades on 2026-07-07 under a Rule 10b5-1 trading plan.
1 min readVera Therapeutics (Nasdaq: VERA) said Chief Regulatory Officer William Turner plans to retire in the third quarter and become Strategic Advisor. Nancy Boman, M.D., Ph.D., will succeed him as Chief Regulatory Officer. The company links Turner’s tenure to the accelerated approval of TRUTAKNA (atacicept-vymj) for IgA nephropathy proteinuria.
3 min readVera Therapeutics, Inc. (VERA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001831828 0001831828 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 09,
2 min readVera Therapeutics (NASDAQ:VERA) shares rose about 9% after the FDA approved Trutakna under the accelerated approval pathway for IgA nephropathy. Interim Phase 3 ORIGIN 3 data for 203 participants showed statistically significant proteinuria reductions vs placebo (42% at 36 weeks; 46% UPCR reduction from baseline). Confirmatory benefit depends on ongoing ORIGIN 3 results expected in Q3 2026.
5 min readVera Therapeutics (Nasdaq: VERA) said the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. In ORIGIN 3 interim analysis, TRUTAKNA cut UPCR 46% vs baseline and 42% vs placebo (statistically significant). Safety in 428 patients included infections (32% vs 28%) and injection reactions (30% vs 5%); long-term kidney benefit pending Q3 2026.
4 min readVera Therapeutics (Nasdaq: VERA) said the FDA granted accelerated approval to TRUTAKNA (atacicept-vymj) for adults with primary IgA nephropathy at risk of progression. In ORIGIN 3 interim analysis, TRUTAKNA reduced proteinuria (UPCR) 46% vs baseline and 42% vs placebo at 36 weeks (p<0.0001). Common AEs were infections and local reactions; long-term kidney benefit not yet established.
6 min readVera Therapeutics’ (NASDAQ:VERA) shares rose about 1% to $41.60 Monday after gaining ~30% over the past month. The company is awaiting an FDA decision due July 7 on accelerated approval of atacicept for IgA nephropathy, supported by ORIGIN 3 interim data showing proteinuria reductions vs placebo. eGFR results are expected in Q3 2026.
3 min readU.S. stock index futures rose premarket as investors returned from a holiday. Scilex Holding gained 7% on a binding term sheet for a proposed $100M strategic investment. Vera Therapeutics rose 6% ahead of a July 7 FDA PDUFA decision for atacicept. Solaris Energy Infrastructure rose 3.9% after Wolfe Research coverage and a ~$55M acquisition. Strategy rose 3.4% after adopting a framework to selectively monetize up to $1.25B in Bitcoin holdings.
4 min readVera Therapeutics’ (NASDAQ:VERA) shares rose ahead of an FDA PDUFA decision on July 7 for its BLA seeking accelerated approval of atacicept in adults with IgA nephropathy. The FDA will decide on the application; Vera says it aligned on a revised ORIGIN 3 eGFR analysis plan, with results expected in Q3 2026.
4 min read
